Public Alert No. 012/2023 – Important Safety Communication: Risk of Ocular Adverse Events with Miltefosine
, The National Agency for Food and Drugs Administration and Control (NAFDAC) is informing the public of risk of ocular adverse effects from the use of miltefosine for the treatment of Post-Kala-Azar Dermal Leishmaniasis (PKDL). This information came as a result of investigation of a signal of ocular adverse events in patients exposed to miltefosine […]